Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.70 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.62 |
| ▸ | HTT | P42858 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7683792 | 0.83 | KDR (1.00) | KDRFGFR1HTTALDH1A1MAPT | |
| SCHEMBL973453 | 0.81 | FGFR1 (0.54) | KDRFGFR1HTTALDH1A1MAPT | |
| SCHEMBL18609552 | 0.79 | KDR (0.74) | KDRFGFR1HTTALDH1A1MAPT | |
| SCHEMBL8006768 | 0.77 | FGFR1 (1.00) | KDRFGFR1HTTALDH1A1MAPT | |
| SCHEMBL19781594 | 0.76 | ATM (0.58) | KDRFGFR1HTTALDH1A1MAPT | |
| SCHEMBL769341 | 0.76 | MAPT (0.70) | KDRFGFR1HTTALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL7989899 | 0.76 | FGFR1 (0.97) | KDRFGFR1HTTALDH1A1MAPT | |
| SCHEMBL2644889 | 0.76 | FGFR1 (0.80) | KDRFGFR1HTTALDH1A1MAPT | |
| SCHEMBL16656278 | 0.75 | KDR (0.67) | KDRFGFR1HTTSRC | |
| SCHEMBL13241207 | 0.75 | EGFR (0.50) | KDRHTTALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871746-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2014-10-28 | — | — | US | claimed |
| US-20120071447-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES INC. (US) | 2012-03-22 | — | — | US | claimed |
| US-8871746-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120071447-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071447-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | ZC3HAV1, GZMB, GTF3C3 | KDR 4519/4885FGFR1 4803/4885HTT 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.